PDE4-IN-6
PDE4-IN-6 is a potent, safe and moderately selective PDE4 inhibitor with IC50s of 0.125 and 0.43 µM for PDE4B and PDE4D, respectively. PDE4-IN-6 can downregulate the expression level of TNF-α and IL-6. PDE4-IN-6 has potent immunomodulatory activity thereby its potential against rheumatoid arthritis. Anti-inflammatory and anti-arthritic effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C25H20FNO5S
- Masse moléculaire:465.49
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
|
PDE4B 0.125 μM (IC50) |
PDE4D 0.43 μM (IC50) |
In Vitro
PDE4-IN-6 (compound 5f) (0.1-10 µM; 1 hour) has concentration-dependent inhibition on TNF-α in Raw 264.7 cells, with 42.3, 49.6, 57.2 and 68.7% inhibition at concentration of 0.3, 1, 3 and 10 µM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Raw 264.7 cells[1]
-
Concentration:0.1-10 µM
-
Incubation Time:1 hour
-
Result:Showed concentration-dependent inhibition on TNF-α, with 42.3, 49.6, 57.2 and 68.7% inhibition at concentration of 0.3, 1, 3 and 10 µM.
In Vivo
PDE4-IN-6 (1-100 μM; incubated 4 days, 3 days or 4 hours) does not induce teratogenicity, hepatotoxicity and cardiac toxicity in zebrafish embryos[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adjuvant-induced arthritis (AIA) albino wistar rats (150-200 g)[1]
-
Dosage:10 and 30 mg/kg
-
Administration:i.p.; daily from day 11 until day 20
-
Result:Improved body weight and reduced paw swelling, also ameliorated joint space narrowing, cartilage degeneration and joint structural deformity at dosing 30 mg/kg, depicting the anti-inflammatory and anti-arthritic effects in AIA model.
Chemical Information
-
Masse moléculaire 465.49
-
Formule C25H20FNO5S
-
SMILES
CC(CCC1=C(OC(C2=CC(F)=CC=C21)=O)C3=CC(NS(=O)(C4=CC=CC=C4)=O)=CC=C3)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)